Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $126,673.94 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) COO Peter Radovich sold 2,627 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $126,673.94. Following the sale, the chief operating officer now owns 26,961 shares in the company, valued at approximately $1,300,059.42. This represents a 8.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Peter Radovich also recently made the following trade(s):

• On Friday, January 24th, Peter Radovich sold 3,177 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total value of $152,241.84.
• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total value of $85,554.36.

Mirum Pharmaceuticals Price Performance

NASDAQ MIRM traded down $0.17 during trading hours on Friday, reaching $51.06. 616,405 shares of the stock traded hands, compared to its average volume of 532,217. The stock has a 50 day simple moving average of $44.80 and a two-hundred day simple moving average of $42.31. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $53.49. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The company has a market cap of $2.45 billion, a price-to-earnings ratio of -25.28 and a beta of 0.96.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. During the same quarter last year, the firm earned ($0.57) EPS. The firm's quarterly revenue was up 89.4% compared to the same quarter last year. On average, analysts predict that Mirum Pharmaceuticals, Inc. will post -1.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. State Street Corp boosted its stake in shares of Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company's stock valued at $69,955,000 after purchasing an additional 297,511 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Mirum Pharmaceuticals by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company's stock worth $12,798,000 after buying an additional 17,149 shares during the last quarter. Geode Capital Management LLC lifted its position in Mirum Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company's stock valued at $36,519,000 after acquiring an additional 29,017 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of Mirum Pharmaceuticals by 791.7% during the third quarter. GSA Capital Partners LLP now owns 57,985 shares of the company's stock valued at $2,261,000 after buying an additional 51,482 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 25.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company's stock valued at $6,021,000 after acquiring an additional 29,545 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on MIRM shares. Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. Citigroup raised their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. HC Wainwright reaffirmed a "buy" rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Leerink Partners lifted their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an "outperform" rating in a research note on Thursday, October 17th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.